Medicare Enrolled
Dr. Daniel Mirda, M.D.
Hematology · Napa, CA
Practice pattern: Mixed Practice
— Diverse clinical practice across multiple procedure types
Consulting-driven
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Mirda from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Mirda?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Mirda
Dr. Daniel Mirda is a hematology specialist in Napa, CA, with 20 years of NPI registration. Based on federal Medicare data, Dr. Mirda performed 31,055 Medicare services across 855 unique beneficiaries.
Between the years covered by Open Payments, Dr. Mirda received a total of $63,060 from 66 pharmaceutical and/or device companies across 321 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Mirda is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 20 years in practice
▲ Top 2% volume in CA
$63,060 industry payments
Medicare Practice Summary
Medicare Utilization ↗31,055
Medicare services
Top 2% in CA for hematology
855
Unique beneficiaries
$12
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~1,553 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Darbepoetin injection (Aranesp) for anemia An injection of darbepoetin alfa used for non-end-stage renal disease purposes. |
21,581 | $2 | $19 |
| Denosumab injection (Prolia/Xgeva) | 7,741 | $18 | $34 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
727 | $148 | $485 |
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
283 | $100 | $345 |
| Drug injection, under skin or into muscle A procedure involving the administration of a medication or substance via injection into the subcutaneous tissue or muscle. |
275 | $13 | $39 |
| Telephone medical discussion, 21-30 minutes A telephone conversation with a physician lasting between 21 and 30 minutes. This code covers the time spent discussing medical matters over the phone. |
146 | $100 | $345 |
| New patient office visit, complex (60-74 min) | 69 | $180 | $591 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
64 | $101 | $266 |
| Leuprolide acetate (for depot suspension), 7.5 mg | 51 | $135 | $800 |
| Subcutaneous or intramuscular chemotherapy injection This procedure involves administering anti-cancer hormonal medication through an injection into the tissue under the skin or into a muscle. |
42 | $32 | $94 |
| Hospital follow-up visit, moderate complexity Follow-up hospital visit for an existing patient involving moderate medical decision making. The visit requires at least 35 minutes of time spent on the date of service. |
41 | $67 | $185 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
35 | $147 | $514 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$63,060
Total received (2018-2024)
Avg $9,009/year across 7 years
Top 21% in CA for hematology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
66
Companies
321
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$30,206 (47.9%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$25,102 (39.8%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$7,753 (12.3%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$2,476
2023
$22,724
2022
$2,351
2021
$5,627
2020
$4,954
2019
$10,664
2018
$14,264
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
PFIZER INC.
$1,491
E.R. Squibb & Sons, L.L.C.
$199
Janssen Biotech, Inc.
$160
ABBVIE INC.
$105
Takeda Pharmaceuticals U.S.A., Inc.
$84
Novartis Pharmaceuticals Corporation
$49
AstraZeneca Pharmaceuticals LP
$45
Lilly USA, LLC
$34
Stemline Therapeutics Inc.
$34
Bayer Healthcare Pharmaceuticals Inc.
$32
GlaxoSmithKline, LLC.
$30
ADC Therapeutics America, Inc.
$30
Daiichi Sankyo Inc.
$29
Tempus AI, Inc
$28
Rigel Pharmaceuticals, Inc.
$24
Celgene Corporation
$24
Mirati Therapeutics, Inc.
$22
Genentech USA, Inc.
$20
Adaptive Biotechnologies Corporation
$20
Merck Sharp & Dohme LLC
$15
Top 3 companies account for 74.8% of 2024 payments
All-time payments by company (2018-2024) ›
GENZYME CORPORATION
$18,210
Eli Lilly and Company
$15,388
E.R. Squibb & Sons, L.L.C.
$8,844
PFIZER INC.
$3,268
Celgene Corporation
$2,295
Eisai Inc.
$1,886
Amgen Inc.
$1,682
Seattle Genetics, Inc.
$1,643
Seagen Inc.
$1,555
Gilead Sciences, Inc.
$1,340
Immunomedics, Inc.
$1,300
Takeda Pharmaceuticals U.S.A., Inc.
$868
Janssen Biotech, Inc.
$548
Lilly USA, LLC
$472
Genentech USA, Inc.
$405
AstraZeneca Pharmaceuticals LP
$359
Novartis Pharmaceuticals Corporation
$223
Monteris Medical Corporation
$174
Kyowa Kirin, Inc.
$146
Novocure Inc.
$145
AbbVie, Inc.
$144
Pharmacyclics LLC, An AbbVie Company
$141
ABBVIE INC.
$130
JAZZ PHARMACEUTICALS INC.
$125
EISAI INC.
$125
Dova Pharmaceuticals
$117
Janssen Scientific Affairs, LLC
$106
Taiho Oncology, Inc.
$100
Astellas Pharma US Inc
$90
Merck Sharp & Dohme LLC
$81
Incyte Corporation
$74
Dendreon Pharmaceuticals LLC
$70
Acrotech Biopharma LLC
$64
Kite Pharma, Inc.
$58
Foundation Medicine, Inc.
$54
Bayer HealthCare Pharmaceuticals Inc.
$48
GlaxoSmithKline, LLC.
$47
Daiichi Sankyo Inc.
$43
TOLMAR Pharmaceuticals, Inc.
$42
Regeneron Healthcare Solutions, Inc.
$38
Merck Sharp & Dohme Corporation
$36
Stemline Therapeutics Inc.
$34
Bayer Healthcare Pharmaceuticals Inc.
$32
Jazz Pharmaceuticals Inc.
$31
ADC Therapeutics America, Inc.
$30
Puma Biotechnology, Inc.
$28
TESARO, Inc.
$28
Tempus AI, Inc
$28
Radius Health, Inc.
$27
G1 Therapeutics, Inc.
$25
Rigel Pharmaceuticals, Inc.
$24
ARRAY BIOPHARMA INC
$24
BeiGene USA, Inc.
$23
CTI BioPharma Corp.
$23
Mirati Therapeutics, Inc.
$22
Janssen Pharmaceuticals, Inc
$22
TG THERAPEUTICS, INC.
$20
Sirtex Medical Inc
$20
Adaptive Biotechnologies Corporation
$20
SOBI, INC
$19
TerSera Therapeutics LLC
$18
Sobi, Inc
$18
Exelixis Inc.
$17
PharmaEssentia USA Corporation
$17
AMAG Pharmaceuticals, Inc.
$13
Alexion Pharmaceuticals, Inc.
$13
Top 3 companies account for 67.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · Abraxane · Alecensa · Avastin · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · BRUKINSA · CALQUENCE · CAMZYOS · COSELA · CYRAMZA · Cabometyx · DARZALEX · DOPTELET · Doptelet · ELAHERE · ELIGARD · ELIQUIS · EMPLICITI · ENHERTU · EPKINLY · ERLEADA · Enhertu · Erleada · FASLODEX · FERAHEME · FOUNDATIONONE · FRUZAQLA · Fabhalta · IBRANCE · ICLUSIG · IMBRUVICA · IMFINZI · INLYTA · Imbruvica · JADENU · JAYPIRCA · JEVTANA · KEYTRUDA · KRAZATI · Kyprolis · LIBTAYO · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Lunsumio · MEKINIST · MONJUVI · NINLARO · Nerlynx · Neulasta · Neuroblate · None · Nplate · Nubeqa · OJJAARA · OPDIVO · OPDUALAG · Optune · Orserdu · PADCEV · PEMAZYRE · PIQRAY · POTELIGEO · PROVENGE · Padcev · Perjeta · Pomalyst · REBLOZYL · RETEVMO · RYBREVANT · Revlimid · Rezlidhia · SHINGRIX · SIR-Spheres Microspheres · SPRYCEL · SUTENT · TAGRISSO · TASIGNA · TECENTRIQ · TECVAYLI · TUKYSA · Tecentriq · Trodelvy · Tymlos · UKONIQ · ULTOMIRIS · VENCLEXTA · VERZENIO · VOTRIENT · VYXEOS · Venclexta · Vonjo · XALKORI · XARELTO · XTANDI · Xermelo · Xofigo · Xospata · ZEJULA · ZEPZELCA · clonoSEQ
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
The majority of payments (48%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.
Geographic Context
Hematologists within 10 mi
2
Per 100K population
1.5
County median income
$108,970
Nearest hospital
PROVIDENCE QUEEN OF THE VALLEY MEDICAL CENTER
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Mirda is a mixed practice specialist, with above-average Medicare volume (top 2% in CA), with consulting-driven industry engagement, with 20 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Mirda experienced with darbepoetin injection (aranesp) for anemia?
Based on Medicare claims data, Dr. Mirda performed 21,581 darbepoetin injection (aranesp) for anemia services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Mirda receive payments from pharmaceutical companies?
Yes. Dr. Mirda received a total of $63,060 from 66 companies across 321 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Mirda's costs compare to other hematologists in Napa?
Dr. Mirda's average Medicare payment per service is $12. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Mirda) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematologists in Napa
Browse hematologists in Napa ranked by procedure volume and transparency data.
Highest volume
Top Hematologists in CA
Hematologists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematologists in CA
Which CA hematologists receive the most from drug and device companies.
By company
GENZYME CORPORATION Payments to Doctors
See all physicians who received payments from GENZYME CORPORATION.
By company
Eli Lilly and Company Payments to Doctors
See all physicians who received payments from Eli Lilly and Company.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology